kymr-10q_20200930.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________________ to ___________________

Commission File Number: 001-39460

 

KYMERA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

81-2992166

(State or other jurisdiction of

incorporation or organization

(I.R.S. Employer
Identification No.)

 

 

200 Arsenal Yards Blvd., Suite 230

Watertown, Massachusetts

02472

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (857) 285-5300

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

KYMR

 

The Nasdaq Global Market 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☐    No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒    No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ☐    No  

As October 30, 2020, the registrant had 44,458,941 shares of common stock, $0.0001 par value per share, outstanding.

 

 


Summary of the Material and Other Risks Associated with Our Business

 

 

We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable.

 

 

We have incurred significant operating losses in recent periods and anticipate that we will incur continued losses for the foreseeable future.

 

 

We will need to raise substantial additional funding. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts.

 

 

We are very early in our development efforts and our IRAK4, IRAKIMiD, and STAT3 programs are still in preclinical development. If we are unable to advance them into and through the clinic for safety or efficacy reasons or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.

 

 

Our approach to the discovery and development of product candidates based on our Pegasus platform is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products.

 

 

Business interruptions resulting from the coronavirus disease (COVID-19) outbreak or similar public health crises could cause a disruption of the development of our product candidates and adversely impact our business.

 

 

We may not be successful in our efforts to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

 

 

If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

 

 

Our current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

 

 

Even if we receive regulatory approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.

 

 

We rely, and expect to continue to rely, on third parties to conduct our ongoing and planned clinical trials for our current and future product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our current and potential future product candidates and our business could be substantially harmed.

 

 

If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.


i


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, express or implied statements about:

 

the initiation, timing, progress, results, and cost of our research and development programs, and our current and future preclinical and future clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;

 

our ability to continue to construct Pegasus, our drug discovery platform, and to enable a rational and effective drug discovery and development engine;

 

the timing and the success of preclinical studies under our IRAK4, IRAKIMiD, and STAT3 programs;

 

our plans to submit investigational new drug applications to the FDA for KT-474 and future product candidates;

 

the subsequent initiation of planned clinical trials;

 

our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities;

 

our potential ability to manufacture our drug substances, delivery vehicles, and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;

 

the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;

 

our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;

 

our ability to obtain and maintain regulatory approval of our product candidates;

 

our ability to commercialize our products, if approved;

 

the pricing and reimbursement of our product candidates, if approved;

 

the implementation of our business model, and strategic plans for our business, product candidates, and technology;

 

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

 

estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;

 

the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;

 

future agreements with third parties in connection with the commercialization of product candidates and any other approved product;

 

the size and growth potential of the markets for our product candidates, and our ability to serve those markets;

 

our financial performance;

 

the rate and degree of market acceptance of our product candidates;

 

regulatory developments in the United States and foreign countries;

 

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

 

our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;

 

the success of competing therapies that are or may become available;

ii


 

our ability to attract and retain key scientific or management personnel;

 

the impact of laws and regulations;

 

developments relating to our competitors and our industry;

 

the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials;

 

our expectations regarding the time during which we will continue to be an emerging growth company or smaller reporting company as defined in federal securities regulations; and

 

other risks and uncertainties, including those listed under the caption “Risk Factors.”

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.


iii


Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

1

Item 1.

Financial Statements (Unaudited)

1

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Operations

2

 

Condensed Consolidated Statements of Comprehensive Loss

2

 

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ (Deficit) Equity

3

 

Condensed Consolidated Statements of Cash Flows

5

 

Notes to Unaudited Condensed Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

22

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

32

Item 4.

Controls and Procedures

32

PART II.

OTHER INFORMATION

33

Item 1.

Legal Proceedings

33

Item 1A.

Risk Factors

33

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

74

Item 3.

Defaults Upon Senior Securities

75

Item 4.

Mine Safety Disclosures

75

Item 5.

Other Information

75

Item 6.

Exhibits

76

Signatures

77

 

 

 

 

iv


PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for share and per share amounts)

(Unaudited)

 

 

 

September 30,

2020

 

 

December 31,

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

54,593

 

 

$

76,015

 

Marketable securities (Note 4)

 

 

239,248

 

 

 

15,942

 

Contract assets

 

 

577

 

 

 

 

Prepaid expenses and other current assets

 

 

2,946

 

 

 

888

 

Total current assets

 

$

297,364

 

 

$

92,845

 

Marketable securities, non-current (Note 4)

 

 

187,464

 

 

 

 

Property and equipment, net (Note 6)

 

 

10,984

 

 

 

3,794

 

Right-of-use assets, operating leases

 

 

9,959

 

 

 

18,289

 

Other assets

 

 

1,590

 

 

 

1,774

 

Total assets

 

$

507,361

 

 

$

116,702

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,979

 

 

$

3,276

 

Accrued expenses (Note 8)

 

 

7,874

 

 

 

4,568

 

Deferred revenue, current

 

 

92,011

 

 

 

23,349

 

Operating lease liabilities, current portion

 

 

2,733

 

 

 

2,696

 

Finance liabilities, current portion

 

 

689

 

 

 

681

 

Total current liabilities

 

$

107,286

 

 

$

34,570

 

Non-current liabilities

 

 

 

 

 

 

 

 

Deferred revenue, net of current portion

 

 

90,308

 

 

 

29,642

 

Operating lease liabilities, net of current portion

 

 

14,327

 

 

 

16,651

 

Finance lease liabilities, net of current portion

 

 

755

 

 

 

1,165

 

Total liabilities

 

$

212,676

 

 

$

82,028

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

 

 

Series Seed Convertible Preferred Stock, $0.0001 par value; 0 and 3,000,000 shares authorized, issued and

   outstanding at September 30, 2020 and December 31, 2019, respectively

 

$

 

 

$

5,900

 

Series A Convertible Preferred Stock, $0.0001 par value; 0 and 14,886,305 shares authorized and issued at

   September 30, 2020 and December 31, 2019, respectively and 0 and 14,720,126 shares outstanding at

   September 30, 2020 and December 31, 2019, respectively

 

 

 

 

 

29,237

 

Series B Convertible Preferred Stock, $0.0001 par value; 0 shares and 16,009,848 authorized at

   September 30, 2020 and December 31, 2019, respectively and 0 and 14,827,580 shares issued

   and outstanding at September 30, 2020 and December 31, 2019, respectively

 

 

 

 

 

59,918

 

Series B-1 Convertible Preferred Stock, $0.0001 par value; 0 and 3,059,695 shares authorized, issued

   and outstanding at September 30, 2020 and December 31, 2019, respectively

 

 

 

 

 

14,025

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 10,000,000 and 0 shares authorized as of September 30, 2020 and

   December 31, 2019, respectively; 0 shares issued or outstanding as of September 30, 2020 and

   December 31, 2019

 

 

 

 

 

 

Common stock, $0.0001 par value; 150,000,000 and 45,000,000 shares authorized at September 30, 2020 and

   December 31, 2019, 44,581,051 and 2,208,982 shares issued at September 30, 2020 and December 31, 2019,

   respectively, and 44,447,734 and 1,929,516 shares outstanding at September 30, 2020 and December 31,

   2019, respectively

 

 

4

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

410,925

 

 

 

2,044

 

Accumulated deficit

 

 

(116,080

)

 

 

(76,456

)

Accumulated other comprehensive (loss) income

 

 

(164

)

 

 

6

 

Total stockholders’ equity (deficit)

 

 

294,685

 

 

 

(74,406

)

Total liabilities, convertible preferred stock and stockholders’ equity (deficit)

 

$

507,361

 

 

$

116,702

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1


 

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Three and Nine Months Ended September 30, 2020 and 2019

(In thousands, except for share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Collaboration Revenue—from related parties

 

$

14,533

 

 

$

950

 

 

$

21,249

 

 

$

1,101

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

15,778

 

 

$

11,310

 

 

$

41,713

 

 

$

26,072

 

General and administrative

 

 

6,838

 

 

 

1,501

 

 

 

13,058

 

 

 

5,451

 

Total operating expenses

 

 

22,616

 

 

 

12,811

 

 

 

54,771

 

 

 

31,523

 

Loss from operations

 

 

(8,083

)

 

 

(11,861

)

 

 

(33,522

)

 

 

(30,422

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Income

 

 

125

 

 

 

445

 

 

 

702

 

 

 

705

 

Interest Expense

 

 

(28

)

 

 

(4

)

 

 

(88

)

 

 

(16

)

Total other income:

 

 

97

 

 

 

441

 

 

 

614

 

 

 

689

 

Net loss

 

$

(7,986

)

 

$

(11,420

)

 

$

(32,908

)

 

$

(29,733

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on marketable securities

 

 

(195

)

 

 

 

 

 

(170

)

 

 

 

Total comprehensive loss

 

$

(8,181

)

 

$

(11,420

)

 

$

(33,078

)

 

$

(29,733

)

Reconciliation of net loss to net loss attributable to common

   stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$

(7,986

)

 

$

(11,420

)

 

$

(32,908

)

 

$

(29,733

)

Deemed dividend from exchange of convertible preferred stock

 

 

 

 

 

 

 

 

(9,050

)

 

 

 

Net loss attributable to common stockholders

 

$

(7,986

)

 

$

(11,420

)

 

$

(41,958

)

 

$

(29,733

)

Net loss per share attributable to common stockholders, basic

   and diluted

 

$

(0.39

)

 

$

(6.54

)

 

$

(5.11

)

 

$

(18.15

)

Weighted average common stocks outstanding, basic and diluted

 

 

20,677,392

 

 

 

1,745,404

 

 

 

8,211,003

 

 

 

1,638,579

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

2


KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY

For the three months ended September 30, 2020 and 2019

(In thousands, except for share amounts)

(Unaudited)

 

 

Series Seed

Convertible

Preferred

Stock

 

Series A

Convertible

Preferred

Stock

 

Series B

Convertible

Preferred

Stock

 

Series B-1

Convertible

Preferred

Stock

 

Series C

Convertible

Preferred

Stock

 

 

 

Common Stock

 

Additional

Paid in

 

Accumulated

 

Accumulated

Other

Comprehensive

 

Consolidated

Members’

and

Stockholders’

Equity

 

 

Shares

 

Value

 

Shares

 

Value

 

Shares

 

Value

 

Shares

 

Value

 

Shares

 

Value

 

 

 

Shares

 

Value

 

Capital

 

Deficit

 

Income (Loss)

 

(Deficit)

 

Balance at June 30, 2019

 

3,000,000

 

$

5,900

 

 

14,609,335

 

$

29,016

 

 

9,605,905

 

$

38,735

 

 

3,059,695

 

$

14,024

 

 

 

$

 

 

 

 

1,697,293

 

$

 

 

1,442

 

$

(53,523

)

$

 

$

(52,081

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of Series A Preferred

   Stock in connection with

   collaboration arrangement

   (Note 5)

 

 

 

 

 

55,395

 

 

110

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Stock Options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

75,565

 

 

 

 

43

 

 

 

 

 

 

43

 

Vesting Restricted Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

91,828

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

   expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

234

 

 

 

 

 

 

234

 

Net Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,420

)

 

 

 

(11,420

)

Balance at September 30, 2019

 

3,000,000

 

$

5,900

 

 

14,664,730

 

$

29,126

 

 

9,605,905

 

$

38,735

 

 

3,059,695

 

$

14,024

 

 

 

$

 

 

 

 

1,864,686

 

$

 

$

1,719

 

$

(64,943

)

$

 

$

(63,224

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2020

 

3,000,000

 

$

5,900

 

 

12,842,112

 

$

25,509

 

 

16,009,845

 

$

64,718

 

 

3,059,695

 

$

14,025

 

 

15,527,943

 

$

101,180

 

 

 

 

2,035,956

 

$

 

 

774

 

$

(108,094

)

$

31

 

$

(107,289

)

Exercise of Stock Options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

51,518

 

 

 

 

110

 

 

 

 

 

 

110

 

Vesting Restricted Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

70,852

 

 

 

 

111

 

 

 

 

 

 

111

 

Stock-based compensation

   expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,328

 

 

 

 

 

 

2,328

 

Unrealized loss on marketable

   securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(195

)

 

(195

)

Issuance of shares in connection

   with initial public offering net

   of underwriting discounts and

   offering costs of $17,003

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9,987,520

 

 

1

 

 

182,746

 

 

 

 

 

 

182,747

 

Conversion of convertible

   preferred stock into

   common stock

 

(3,000,000

)

$

(5,900

)

 

(12,842,112

)

$

(25,509

)

 

(16,009,845

)

$

(64,718

)

 

(3,059,695

)

$

(14,025

)

 

(15,527,943

)

$

(101,180

)

 

 

 

31,625,534

 

 

3

 

 

211,329

 

 

 

 

 

 

211,332

 

Issuance of shares in concurrent

   private placement

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

676,354

 

 

 

 

 

13,527

 

 

 

 

 

 

 

 

13,527

 

Net Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,986

)

 

 

 

(7,986

)

Balance at September 30, 2020

 

 

$

 

 

 

$

 

 

 

$

 

 

 

$

 

 

 

$

 

 

 

 

44,447,734

 

 

4

 

$

410,925

 

$

(116,080

)

$

(164

)

$

294,685

 

3


 

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY (continued)

For the nine months ended September 30, 2020 and 2019

(In thousands, except for share amounts)

(Unaudited)

 

 

Series Seed

Convertible

Preferred

Stock

 

Series A

Convertible

Preferred

Stock

 

Series B

Convertible

Preferred

Stock

 

Series B-1

Convertible

Preferred

Stock

 

Series C

Convertible

Preferred

Stock

 

 

 

Common Stock

 

Additional

Paid in

 

Accumulated

 

Accumulated

Other

Comprehensive

 

Consolidated

Members’

and

Stockholders’

Equity

 

 

Shares

 

Value

 

Shares

 

Value

 

Shares

 

Value

 

Shares

 

Value

 

Shares

 

Value

 

 

 

Shares

 

Value

 

Capital

 

Deficit

 

Income (Loss)

 

(Deficit)

 

Balance at December 31, 2018

 

3,000,000

 

$

5,900

 

 

14,498,547

 

$

28,794

 

 

9,605,905

 

$

38,735

 

 

 

$

 

 

 

$

 

 

 

 

1,479,188

 

$

 

 

774

 

$

(35,210

)

$

 

$

(34,436

)

Vesting of Series A Preferred

   Stock in connection with

   collaboration arrangement

   (Note 5)

 

 

 

 

 

166,183

 

 

332

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of Series B-1 Preferred

   Stock, net of issuance costs

   of $49

 

 

 

 

 

 

 

 

 

 

 

 

 

3,059,695

 

 

14,024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Stock Options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

77,616

 

 

 

 

46

 

 

 

 

 

 

46

 

Vesting Restricted Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

307,882

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

   expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

899

 

 

 

 

 

 

899

 

Net Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(29,733

)

 

 

 

(29,733

)

Balance at September 30, 2019

 

3,000,000

 

$

5,900

 

 

14,664,730

 

$

29,126

 

 

9,605,905

 

$

38,735

 

 

3,059,695

 

$

14,024

 

 

 

$

 

 

 

 

1,864,686